Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity

References

• Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes 1995;44:369-74
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Diabetes Surveillance Report. CDC, USDHHS; 1999
   Google Scholar
• Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2009;87:4-14
   PubMed Web of Science ®Google Scholar
• Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-81
   PubMed Web of Science ®Google Scholar
• Lindström J, Tuomilehto J. The diabetes risk score: a practical score to predict risk of type two diabetes. Diabetes Care 2003;26:725-31
   PubMed Web of Science ®Google Scholar
• McNeely MJ, Boyko EJ, Leonetti DL, et al. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes in Japanese Americans. Diabetes Care 2003;26:758-63. PMID:12610034
   Web of Science ®Google Scholar
• Wilson PWF, Meigs JB, Sullivan L, et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74. PMID:17533210
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Robson J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880
   Google Scholar
• Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012 33:1635-701
   Google Scholar
• European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013. [Epub ahead of print]
   Google Scholar
• Rana JS, Cote M, Després JP, et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk; the EPIC-Norfolk prospective population study. Heart 2009;95:1682-7
   PubMed Web of Science ®Google Scholar
• Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation 2004;109:1349-53
   PubMed Web of Science ®Google Scholar
• Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-9
   PubMed Web of Science ®Google Scholar
• Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Gonzales C, et al. the San Antonio Heart Study, the Mexico City Diabetes Study, the Insulin Resistance Atherosclerosis Study. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003;52:463-9
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Hergenç G, et al. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr Metab Cardiovasc Dis 2012;22:643-50
   Google Scholar
• Chien K, Cai T, Hsu H, et al. A prediction model for type 2 diabetes risk among Chinese people. Diabetologia 2009;52:443-50
   PubMedGoogle Scholar
• Emerging Risk Factors Collaboration. Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analyses of 58 prospective studies. Lancet 2011;377:1085-95
   PubMed Web of Science ®Google Scholar
• Finucane MM, Stevens GA, Cowan MJ, et al. on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborative Group. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-67
   PubMed Web of Science ®Google Scholar
• Song X, Pitkäniemi J, Gao W, et al. Relationship between body mass index and mortality among Europeans. Eur J Clin Nutr 2011;66:156-65
   Google Scholar
• Lu Y, Hajifathalian K, Ezzati M, et al. The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaborating Group (BMI-mediated Effects). Metabolic mediators of the effects of body-mass-index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014;383(9921):970-83
   PubMed Web of Science ®Google Scholar
• Onat A, Aydın M, Can G, et al. Impaired fasting glucose: pro-diabetic, “atheroprotective” and modified by metabolic syndrome. World J Diabetes 2013;4:210-18
   Google Scholar
• Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84
   PubMed Web of Science ®Google Scholar
• Pierre J, Lemieux I, Perron B, et al. Relation of the “hypertriglyceridemic waist” phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol 2007;99:369-73
   Google Scholar
• Arsenault BJ, Lemieux I, Després JP, et al. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. CMAJ 2010;182:1427-32
   PubMed Web of Science ®Google Scholar
• Yu D, Huang J, Hu D, et al. Is an appropriate cutoff of hypertriglyceridemic waist designated for type 2 diabetes among Chinese adults? Clin Nutr 2010;29:192-8
   PubMedGoogle Scholar
• De Graaf FR, Schuijf JD, Scholte AJ, et al. Usefulness of hypertriglyceridemic-waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol 2010;106:1747-53
   PubMedGoogle Scholar
• Onat A, Can G, Örnek E, et al. Abdominal obesity with hypertriglyceridemia, lipoprotein(a) and apoA-I determine marked cardiometabolic risk. Eur J Clin Invest 2013;43:1129-39
   PubMed Web of Science ®Google Scholar
• Duell PB, Hagemenas F, Connor WE. The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men. Diabetes Care 1994;17:1135-40
   PubMed Web of Science ®Google Scholar
• Haffner SM, Karhapaa P, Rainwater DL, et al. Insulin sensitivity and Lp(a) concentrations in normoglycemic men. Diabetes Care 1995;18:193-9
   PubMed Web of Science ®Google Scholar
• De Meester CA, Bu X, Gray RJ, et al. Genetic variation in lipoprotein(a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein(a) gene locus. Am J Hum Genet 1995;56:287-91
   Google Scholar
• Rainwater DL, Mac Cluer JW, Stern MP, et al. Effect of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. Diabetes 1994;43:942-6
   PubMed Web of Science ®Google Scholar
• Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010;55:2160-7
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28
   PubMed Web of Science ®Google Scholar
• Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2030-6
   PubMedGoogle Scholar
• Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010;3:39-46
   PubMed Web of Science ®Google Scholar
• Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014;20:575-84
   PubMed Web of Science ®Google Scholar
• Haffner SM. Lipoprotein(a) and diabetes. Diabetes Care 1993;16:835-40
   Web of Science ®Google Scholar
• Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998;18:1335-41
   PubMed Web of Science ®Google Scholar
• Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than prediabetic men. Diabetologia 1997;40:711-17
   PubMed Web of Science ®Google Scholar
• Zhang L, Qiao Q, Tuomilehto J, et al. DECODE Study Group. The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 2009;206:298-302
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Çiçek G, et al. Fasting, non-fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes, and coronary disease in non-diabetic adults. Acta Diabetol 2013;50:519-28
   PubMed Web of Science ®Google Scholar
• Ning F, Tuomilehto J, Pyörälä K, et al. for the DECODE Study Group. Cardiovascular disease mortality in Europeans in relation to fasting and 2h plasma glucose levels within a normoglycemic range. Diabetes Care 2010;33:2211-16
   PubMed Web of Science ®Google Scholar
• Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298:2654-64
   PubMed Web of Science ®Google Scholar
• Rimm EB, Manson JE, Stampfer MJ, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83:211-14
   PubMed Web of Science ®Google Scholar
• Rasouli B, Grill V, Midthjell K, et al. Smoking is associated with reduced risk of autoimmune diabetes in adults contrasting with increased risk in overweight men with type 2 diabetes: a 22-year follow-up of the HUNT study. Diabetes Care 2013;36:604-10
   Google Scholar
• Onat A, Özhan H, Esen AM, et al. Prospective epidemiologic evidence of a protective effect of smoking on metabolic syndrome and diabetes among Turkish women – without associated overall health benefit. Atherosclerosis 2007;193:380-9
   PubMed Web of Science ®Google Scholar
• Onat A, Ayhan E, Hergenç G, et al. Smoking inhibits visceral fat accumulation in Turkish females: Relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance and blood pressure. Metabolism 2009;58:963-70
   PubMed Web of Science ®Google Scholar
• Onat A, Erginel-Unaltuna N, Coban N, et al. APOC3 -482C>T polymorphism, circulating apolipoprotein C-III and smoking: Interrelation and roles in predicting type-2 diabetes and coronary disease. Clin Biochem 2011;44:391-6
   Google Scholar
• Nagaya T, Yoshida H, Takahashi H, Kawai M. Heavy smoking raises risk for type 2 diabetes mellitus in obese men; but, light smoking reduces the risk in lean men: a follow-up study in Japan. Ann Epidemiol 2008;18:113-18
   Google Scholar
• Kwasniewska M, Pikala M, Kaczmarczyk-Chałas K, et al. Smoking status, the menopausal transition, and metabolic syndrome in women. Menopause 2012;19:194-201
   PubMed Web of Science ®Google Scholar
• Holmer SR, Hengstenberg C, Kraft H-G, et al. Associations of the polymorphisms of apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003;107:696-701
   PubMed Web of Science ®Google Scholar
• Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type-2 diabetes. Clin Chem 2010;56:1252-60
   PubMed Web of Science ®Google Scholar
• Ye Z, Haycock PC, Gurdasani D, et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes 2014;63:332-42
   PubMed Web of Science ®Google Scholar
• Qi Q, Workalemahu T, Zhang C, et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012;33:325-34
   PubMed Web of Science ®Google Scholar
• Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemostas 2009;7(Suppl 1):332-9
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, et al. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-35
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011;60:499-512
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Bulur S, et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010;142:72-9
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Ayhan E, et al. Serum apolipoprotein C-III in high-density lipoprotein: A key diabetogenic risk factor among Turks. Diabet Med 2009;26:981-8
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ayhan E, et al. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 2009;58:1393-9
   PubMed Web of Science ®Google Scholar
• Onat A, Hergenç G, Can G, Küçükdurmaz Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity 2009;17:564-70
   Google Scholar
• Onat A, Aydın M, Can G, et al. High adiponectin levels fail to protect against risk of hypertension and, in women, against coronary disease: involvement in autoimmunity? World J Diabetes 2013;5:219-25
   Google Scholar
• Onat A, Çakmak HA, Can G, et al. Serum total and high-density lipoprotein phospholipids: independent predictive value for cardiometabolic risk. Clin Nutr 2013. [Epub ahead of print]
   Google Scholar
• Lohner S, Fekete K, Marosvölgyi T, Decsi T. Gender differences in the long-chain polyunsaturated fatty acid status: systematic review of 51 publications. Ann Nutr Metab 2013;62:98-112
   PubMed Web of Science ®Google Scholar
• Castro-Faria-Neto HC, Stafforini DM, Prescott SM, Zimmerman GA. Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase. Mem Inst Oswaldo Cruz 2005;100(Suppl 1):83-91
   Google Scholar
• Emerging Risk Factors Collaboration. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ciçek G, et al. Coronary disease risk and fasting glucose levels in a non-diabetic population. Diabetes Res Clin Pract 2011;91:220-5
   Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81
   PubMed Web of Science ®Google Scholar
• Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the US. Findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:1337-43
   Google Scholar
• Seshasai SR, Kaptoge S, Thompson A, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation 2014;129:999-1008
   PubMed Web of Science ®Google Scholar
• Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1c and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009;54:422-8
   PubMed Web of Science ®Google Scholar
• Olsson L, Grill V, Midthjell K, et al. Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT Study. Diabetes Care 2013;36:3971-8
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose-lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;374:481-9
   Google Scholar
• Nichols GA, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 2013;62:121-7
   PubMed Web of Science ®Google Scholar
• Huang ES, Liu JY, Moffet HH, et al. Glycemic control, complications, and death in older diabetic patients: the Diabetes and Aging Study. Diabetes Care 2011;34:1329-3
   PubMed Web of Science ®Google Scholar
• Colayco DC, Niu F, McCombs JS, Cheetham TC. A1c and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011:34:77-83
   Google Scholar
• Christman AL, Lazo M, Clark JM, Selvin E. Low glycated hemoglobin and liver disease in the U.S. population. Diabetes Care 2011;34:2548-50
   Google Scholar
• Aggarwal V, Schneider ALC, Selvin E. Low hemoglobin A1c in nondiabetic adults: an elevated risk state? Diabetes Care 2012;35:2055-60
   Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:738-42
   Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in the Women’s Health Initiative. Arch Intern Med 2012;172:144-52
   PubMed Web of Science ®Google Scholar
• Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;30:1231-8
   Google Scholar
• Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-5294
   PubMed Web of Science ®Google Scholar
• Gonbert S, Malinsky S, Sposito AC, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002;164:305-11
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek VJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetemibe. Eur Heart J 2012;33:2939-45
   PubMedGoogle Scholar
• Onat A, Can G, Örnek E, et al. Elevated serum uric acid levels in nondiabetic people mark pro-inflammatory state and HDL dysfunction, and independently predicts coronary disease. Clin Rheumatol 2013;32:1767-75
   PubMed Web of Science ®Google Scholar
• Onat A, Can G, Ademoğlu E, et al. Coronary disease risk curve of serum creatinine is linear in Turkish men, U-shaped in women. J Investig Med 2013;61:27-33
   PubMed Web of Science ®Google Scholar
• Onat A, Yüksel H, Can G, et al. Serum creatinine is associated with coronary disease risk even in the absence of metabolic disorders. Scand J Clin Lab Inv 2013;73:569-7599
   Web of Science ®Google Scholar
• Kuo C-F, See L-C, Yu K-H, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology 2013;52:127-34
   PubMed Web of Science ®Google Scholar